More companies around the world continue turning to Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, for their next-generation sequencing (NGS) needs with the Biomek NGeniuS System.
The company continues building a robust demonstrated application library as it announces an application development agreement with Pillar Biosciences, which specialises in developing and commercialising IVD and RUO NGS testing solutions that help research to optimise selection of precision therapies for cancer patients, from tumour profiling to therapy selection, and recurrence monitoring.
In the traditionally labour-intensive process of NGS library construction, the Biomek NGeniuS System cuts through the clutter by reducing manual steps with an intuitive and easy-to-use automation solution. Hands-on time is cut by innovations that include a reagent input carousel to minimise the manual transfer of reagents, along with an integrated thermal cycler and labware transport system.
With the global NGS market projected to grow to nearly $9.2 billion in 2022, demand is expected to increase for solutions to provide critical assistance to NGS labs.
“As this market segment continues to grow, Beckman Coulter Life Sciences is ready and uniquely positioned to help laboratories of all sizes accelerate answers for important clinical research,” said Amy Yoder, Director of Genomics Product Management. “This partnership with Pillar Biosciences further showcases the strength and appeal of our open chemistry concept that’s exclusive to the Biomek NGeniuS System. With a significant reduction in manual and error-prone steps in the library prep process, we’re excited to pioneer workflows that allow laboratory staff to focus on their passion for research and their vision for the future of molecular diagnostics.”
As part of the partnership agreement, Pillar Biosciences will develop applications specifically designed for the Biomek NGeniuS System, which will be available to all users via a first-of-its-kind electronic application library.
“The ability of laboratories, hospitals, and healthcare systems to support research for accurate, efficient, and cost-effective next generation sequencing technologies and diagnostic testing at the local level with rapid turnaround time, offers the promise to greatly improve the future state of cancer care,” said Randy Prichard, CEO of Pillar Biosciences. “Our partnership with Beckman Coulter Life Sciences to develop and provide automated workflow applications on the Biomek NGeniuS System for our portfolio of oncoReveal kitted solutions, which leverage Pillar’s proprietary single-tube enrichment chemistry, SLIMamp, reaffirms Pillar’s global commitment to helping to drive the localisation of NGS testing and enabling better treatment for everyone, everywhere.”
Launched in June of 2022, the Biomek NGeniuS System includes exclusive software that allows any batch size, from four to 24 samples, to be set up from anywhere and monitored remotely from a Google Chrome or Microsoft Edge-enabled computer. The workstation also reduces loading errors by combining a sophisticated optical analytics technology – Dynamic DeckOptix system – to provide users real-time feedback on labware placement. More product information can be found at becls.co/ngenius.
